H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on the shares following the Q3 report. The firm says new clinical data support the thesis that elironrasib addresses resistance mechanisms to first-generation KRAS inhibitors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines Reports Q3 2025 Financial Results
- Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
- Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
- Revolution Medicines reiterates FY25 GAAP net loss guidance
- Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)